Argenx shares plunge 16% after Sjögren’s drug trial halted

Markets Investing.com By Investing.com 08 Oct 2026 07:39 1 min read
Argenx shares plunge 16% after Sjögren’s drug trial halted

Covered in this story

Call it yourself

No calls on $ARGX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.

Make the first call on argenx →
Read the full story on Investing.com → Opens the original article on www.investing.com

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.